Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton Dublilier & Rice, known as CD&R. The two companies shared that they have ...

Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder. The terms of the transaction remain unchanged from ...

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...

The valuation of Opella was then based on an enterprise value of 16 billion euros. Sanofi now said the agreement follows completion of the required social and corporate procedures. Bpifrance is ...

Sanofi (NASDAQ:SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, its consumer healthcare business, to private equity firm CD&R. The terms of ...

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...